Ikena Oncology, Inc.
NASDAQ:IKNA
1.69 (USD) • At close September 10, 2024
Overzicht | Financiële gegevens
Bedrijfsnaam | Ikena Oncology, Inc. |
Symbool | IKNA |
Munteenheid | USD |
Prijs | 1.69 |
Beurswaarde | 81,556,189 |
Dividendpercentage | 0% |
52-weken bereik | 1.02 - 4.945 |
Industrie | Biotechnology |
Sector | Healthcare |
CEO | Dr. Mark Manfredi Ph.D. |
Website | https://ikenaoncology.com |
An error occurred while fetching data.
Over Ikena Oncology, Inc.
Ikena Oncology, Inc., a targeted oncology company, focuses on developing medicines tailored to biomarker-defined patient groups for specific unmet needs. Its lead targeted oncology product candidate is IK-930, an oral small molecule inhibitor of the transcriptional enhanced associate domain, transcription factor in the Hippo signaling pathway. It is also developing
Vergelijkbare Aandelen
Financiële Gegevens
Cijfers zijn in miljoenen (USD)
Cijfers zijn in miljoenen (USD)